The TAMARACK study uses a test drug that is an Anti-body Drug Conjugate, or ADC, as a potential treatment option for metastatic castrate resistant prostate cancer. An ADC is an antibody with an anti-cancer drug attached. The antibody portion of the ADC brings the anti-cancer drug specifically to the cancer cell, where it will attach to a protein on the outside of the cancer cell. It causes damage leading to the death of the cancer cell. The antibody is specifically targeted to enter cancer cells. 

The study compares two dose levels of the test drug and evaluates effectiveness and side effects.

If your prostate cancer is worsening, you may be eligible.

LEARN MORE

The purpose of this study is to test ways to personalize treatment for patients with prostate cancer that has returned after prostatectomy. The study will assess if the use of PET scans can help identify patients for whom more therapy may lead to better outcomes. All participants will receive the usual treatment (radiation therapy and short-term hormone therapy). In addition:

- Some patients will receive additional PET imaging, depending on the results of their initial PET
- Some patients will also receive a newer type of hormone therapy called apalutamide, which is already approved by the FDA for some prostate cancers
- Some patients, depending on the results of their initial PET scan, will receive metastasis-directed radiation therapy

Learn More

Check out the launch of PROMISE, a new national study led by physicians from Johns Hopkins University and University of Washington!

• PROMISE study researchers seek to:
  Learn more about the critical role of inherited genetic mutations in men with prostate cancer
  Understand how specific inherited genetic mutations may affect prostate cancer treatment response, prostate cancer biology and risk.

Discover if you have a genetic mutation that may impact your treatment plan  Help family members understand their own risk of prostate cancer. Make an essential contribution to advancing research and understanding of prostate cancer.

Learn More

The MAGNITUDE Study is a Phase 3 randomized, placebocontrolled, doubleblind study comparing a combination of an investigational medicine and standard treatment, to a combination of a placebo and standard treatment for men with metastatic prostate cancer.

Learn More

https://clinicaltrials.gov/ct2/show/NCT03748641?term=NCT03748641&rank=1

The AMPLITUDE study is looking for men with newly diagnosed metastatic prostate cancer.

Am I eligible?

You may be able to participate in the AMPLITUDE study if you:
• Are 18 years of age or older
• Have been recently diagnosed with metastatic prostate cancer, which means that cancer
has spread to other parts of the body such as bones, liver, or lung
• Willing to be tested or have already a positive test by blood, tissue, or saliva sample for
specific genetic alterations

If you want to learn more about genetic alterations or biomarkers, please watch this video:
https://content.gtc-api.dev/sites/default/files/2020-08/GTC_OnlineEngagement-
ENG09_Biomarkers_V1.0_040220_Final.mp4

Study design

The AMPLITUDE study is looking at the effectiveness and safety of an investigational combination of
medications compared with a standard prostate cancer therapy. The study is double-blind which
means neither you nor your study doctor will know which medication you will be receiving during
the trial.

Interested in participating?
To learn more about this study, if you may be eligible and if the study is being conducted at a site
near you, please visit: https://clinicaltrials.gov/ct2/show/NCT04497844?recrs=b&cond=niraparib&draw=3&rank=15
or https://globaltrialfinder.janssen.com/

Please Note: This information is provided for education and awareness purposes. A decision on clinical trial participation is to be made between the patient and his doctor.